Spravato® Treatment

Learn Spravato Coding & Reimbursement Now!

Learn Spravato Coding & Reimbursement Now! Navigating the coverage and reimbursement landscape for SPRAVATO® (esketamine) nasal spray requires careful consideration to ensure compliance and optimize reimbursement. The assignment of a Healthcare Common Procedure Coding System (HCPCS) code and a payment rate does not guarantee coverage by Medicare, Medicaid, or private payers. Each payer determines whether […]

Learn Spravato Coding & Reimbursement Now! Read More »

Why Ensuring Payer Contracting for Buy-and-Bill Is Essential Before Implementing Spravato® in Your Practice

Why Ensuring Payer Contracting for Buy-and-Bill Is Essential Before Implementing Spravato® in Your Practice Before adopting the buy-and-bill model for Spravato® (esketamine) nasal spray in your practice, it’s crucial to confirm that the payers in your network are contracted to support this billing method. This step ensures financial sustainability, smooth reimbursement, and optimal patient care.

Why Ensuring Payer Contracting for Buy-and-Bill Is Essential Before Implementing Spravato® in Your Practice Read More »

Understanding the Differences Between Buy-and-Bill and Assignment of Benefits for Spravato® (Esketamine)

Understanding the Differences Between Buy-and-Bill and Assignment of Benefits for Spravato® (Esketamine) Spravato® (esketamine) nasal spray is a groundbreaking treatment for treatment-resistant depression (TRD) and major depressive disorder (MDD) with acute suicidal ideation or behavior. As its use grows, healthcare providers and patients must navigate different payment models to access the medication. Two common billing

Understanding the Differences Between Buy-and-Bill and Assignment of Benefits for Spravato® (Esketamine) Read More »